NATURAL AND INDUCED IMMUNITY AGAINST HELICOBACTER PYLORI

Information

  • Research Project
  • 6403306
  • ApplicationId
    6403306
  • Core Project Number
    R01DK053706
  • Full Project Number
    7R01DK053706-05
  • Serial Number
    53706
  • FOA Number
    RFA-DK-97-03
  • Sub Project Id
  • Project Start Date
    10/2/2000 - 24 years ago
  • Project End Date
    9/29/2002 - 22 years ago
  • Program Officer Name
    HAMILTON, FRANK A
  • Budget Start Date
    10/2/2000 - 24 years ago
  • Budget End Date
    9/29/2001 - 23 years ago
  • Fiscal Year
    2000
  • Support Year
    5
  • Suffix
  • Award Notice Date
    2/7/2001 - 24 years ago

NATURAL AND INDUCED IMMUNITY AGAINST HELICOBACTER PYLORI

DESCRIPTION (taken from the application) Helicobacter pylori is usually acquired during childhood and its prevalence in adults ranges from 20-30% in industrialized countries to 80-90% in developing countries. The prevalence of H. pylori infection is considerably higher in minorities in the US compared to the general population. Infection elicits a sustained host immune response but this is not effective in eliminating the organism. In contrast, oral immunization in mice and ferrets with various H. pylori antigens can prevent and even cure Helicobacter infection, indicating that H. pylori is not beyond the reach of an effective immune response. The mechanisms by which H. pylori persists despite the natural host immune response and those by which oral immunization provides protection or cure remain undefined. The long term goal of this proposal is to develop an effective human vaccine against H. pylori. This will allow control of the infection in the population, a goal that is unlikely to be achieved by antibiotic-based therapies. The immediate goal of this proposal is to acquire a better understanding of the mechanisms by which oral immunization confers protection, thereby enabling the design of an effective human vaccine. Using H. felis infection and urease-based immunization as models, this proposal aims at delineating the origin and the homing pattern of the immune cells that participate in the protection of the gastric mucosa. First, the role of alpha4 Beta7+ lymphocytes in protective immunity after oral immunization with H. pylori urease will be examined in mice. In vivo injection of anti-alpha4 Beta7+ integrin antibodies and passive transfer of alpha4 Beta7+ lymphocytes will be used to define the role of alpha4 Beta7+ lymphocytes in protection. The antigen specificity of alpha4 Beta7+ cells will also be determined. Second, the contribution of MAdCAM-1 addressin to gastric homing of immune cells will be determined in vitro by immunohistochemistry and in vivo by anti-MAdCAM-1 antibody treatment of immunized and challenged animals. Third, alpha4 Beta7+ lymphocytes will be quantified in the peripheral blood of human volunteers immunized with H. pylori urease by different routes of mucosal immunization. The antigen specificity of these cells will also be determined. These experiments will allow a better definition of the immune effector mechanisms engaged in mice during H. felis infection and during mucosal immunization in both mice and humans. These studies may also contribute to the development of effective vaccination strategies against other enteric pathogens.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R01
  • Administering IC
    DK
  • Application Type
    7
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    50000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    848
  • Ed Inst. Type
  • Funding ICs
    NIDDK:50000\
  • Funding Mechanism
  • Study Section
    ZDK1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS
  • Organization Department
  • Organization DUNS
  • Organization City
    LAUSANNE
  • Organization State
  • Organization Country
    SWITZERLAND
  • Organization Zip Code
    1011
  • Organization District
    SWITZERLAND